In patients with HFrEF, liraglutide might increase the risk of cardiovascular adverse effects, an effect possibly driven by excess risk of arrhythmias and worsening HF events (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: liraglutide
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study
In this emulation of the GRADE trial, liraglutide was statistically significantly more effective at maintaining glycemic control than glimepiride or sitagliptin when added to metformin monotherapy. Generating timely evidence on medical treatments using real world data as a complement to prospective trials is of value (BMJ)
Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
The United States Food and Drug Administration (FDA) has approved two GLP-1RAs, liraglutide 1.8 mg/d and exenatide extended-release (ER), for T2D in youth aged 10 years or older.2 However, little is known about GLP-1RA prescribing patterns in youth. The objective of this retrospective chart review was to explore GLP-1RA prescribing practices for adolescents with T2D (Diabetes, Obesity and Metabolism)
Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure
We provided the first evidence that CD34+ HSPC express GLP-1R and that LIRA can favorably impact on cell dysfunction due to HG exposure. These findings open new perspectives on the favorable CV effects of GLP-1 RAs in T2DM patients (Cardiovascular Diabetology)
Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials
Liraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators, and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function (BMC Endocrine Disorders)
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
Liraglutide had beneficial actions on glycemic parameters and cardiometabolic risk factors in both non-obese and obese patients with T2DM, with a greater efficacy in the latter (Diabetes Therapy)
Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials
In patients with T2D, semaglutide/liraglutide offered kidney-protective effects, which appeared more pronounced in those with pre-existing chronic kidney disease (Circulation)
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials
In ADJUNCT ONE and ADJUNCT TWO, the efficacy and glycaemic safety of liraglutide did not depend on subgroups, leaving residual beta-cell function as the only identified variable impacting the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in T1D. These findings support a role for GLP-1 RAs as adjuncts to insulin in T1D, warranting further study (Diabetes, Obesity and Metabolism)
Efficacy and Safety of Liraglutide in Type 1 Diabetes by Baseline Characteristics in the ADJUNCT ONE and ADJUNCT TWO Randomized Clinical Trials
In ADJUNCT ONE and TWO, the efficacy and glycemic safety of liraglutide did not depend on subgroups, leaving residual beta-cell function the only identified parameter impacting the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in T1D (Diabetes, Obesity and Metabolism)
Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: post-hoc analysis of LIRA-ADD2SGLT2i
For individuals with T2D and inadequate glycaemic control despite therapy with SGLT2is±metformin, liraglutide 1.8mg would provide an effective treatment intensification option, irrespective of HbA1c, BMI, diabetes duration, insulin resistance determined by HOMA-IR and SGLT2i use duration (Diabetes, Obesity and Metabolism)
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
The combination of anti-IL-21 and liraglutide could preserve β-cell function in recently diagnosed type 1 diabetes. The efficacy of this combination appears to be similar to that seen in trials of other disease-modifying interventions in type 1 diabetes, but with a seemingly better safety profile (The Lancet Diabetes & Endocrinology)
Effect of liraglutide vs. placebo treatment on circulating proglucagon‐derived peptides that mediate improvements in body weight, insulin secretion and action
Effect of liraglutide vs. placebo treatment on circulating proglucagon‐derived peptides that mediate improvements in body weight, insulin secretion and action (Diabetes, Obesity and Metabolism)
Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis
The clinical effectiveness of liraglutide is maintained long term (up to 5 years). Liraglutide treatment is not associated with higher total direct healthcare costs (Diabetes Therapy)
Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine)
The Leader study has shown that the rate of the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo (ABCD)
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
This implies that liraglutide and semaglutide may be beneficial for patients with type 2 diabetes, irrespective of their baseline BP (Diabetes Obesity and Metbolism)
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: a randomized controlled study ELLENA‐IT study
Liraglutide addition to ongoing insulin therapy effectively reduced glycated hemoglobin and glycated albumin levels than empagliflozin in patients with inadequately controlled type 2 diabetes (Journal of Diabetes Investigation)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy (NEJM)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
Based on these findings, liraglutide should be considered suitable for patients with T2D with or without a history of NYHA functional class I to III HF (Journal of the American College of Cardiology)
Liraglutide as add‐on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
Liraglutide significantly improved glycaemic control compared to placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings (Diabetes, Obesity and Metabolism)
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events
These results suggest that liraglutide treatment is associated with reduced total MACE compared with placebo among patients with type 2 diabetes and high risk of cardiovascular events. This analysis supports the findings of an absolute benefit of liraglutide treatment with respect to the overall burden of cardiovascular events in this high-risk patient population (JAMA Cardiology)
Glycosmedia is also available as an App: